

A3VTF Quarterly Meeting Minutes

April 23, 2024

Hosted by ADPH

WebEx Conference

Moderator:

Joshlynn Edwards, MPH, Public Health Educator Sr., ADPH

- Welcome:
 - Joshlynn Edwards, MPH, ADPH, Immunization Division

- Zoster Disease:
 - Solomon F. Odafe, MBBS, MPH, MSc, Epidemic Intelligence Service Officer, Immunization Services Division, National Center for Immunization & Respiratory Diseases, CDC

- HPV Vaccination is Cancer Prevention:
 - Portia Knowlton, MHRM, Program Coordinator, HPV Cancer Prevention Program, St. Jude

- Next Steps/Adjourn:
 - Joshlynn Edwards, MPH, ADPH, Immunization Division

Alabama Adolescent and Adult Vaccination Task Force (A3VTF)

Hosted by ADPH

WebEx Conference

April 23, 2024

Meeting Participants*

Present:

Leanne Alexander, Merck Vaccine Policy

Daniel Bankson, Alabama Medicaid

Carolyn Bern, ADPH, Governmental Affairs and Community Relations

Richard Beverly, BCBS

Tanita Crowell, ADPH, Immunization Division

Dr. Casey Daniel, University of South Alabama College of Medicine

Angela Davis, AMC

Lamont Dupree, North AL AHEC

Joshlynn Edwards, ADPH, Immunization Division

Tonya Gandy, ADPH

Justin George, ADPH
Barbara Gibbs, MCHD
Calvin Gipson, ADPH, Immunization Division
Kimberly Graham, Alabama Medicaid Agency
Lakita Hawes, ADPH, Cancer Division
Brooke Haynes
Portia Knowlton, St. Jude Hospital
Jaida Lane, ADPH, Immunization Division
Alyssa Lee, University of South Alabama
Karen Leeling, North AL AHEC
Kelli Littlejohn, AMA
Meg Mc, Laura Crandall Brown Foundation
Amy Morris, ADPH, FHS
Patrick Neither, Merck
Kitty Norris, ADPH
Solomon Odafe, CDC
Jerome Pinson, CSL Seqirus
Savannah Robinson, ADPH, Immunization Division
Dr. Wes Stubblefield, ADPH, District Medical Officer
Stephanie Thomas, ADPH, Immunization Division
Chevonne Tyner, ADPH, Immunization Division
Kassi Webster, BCBS
Nancy Wright, ADPH
Brandon Young, CSL Seqirus

**Note: If you attended the meeting and your name/organization isn't listed above, please submit an email to Joshlynn.Edwards@adph.state.al.us confirming your attendance.*

Meeting Minutes

Introductions:

- The meeting was called to order at 10:00 am by Joshlynn Edwards, ADPH, Immunization Division. Ms. Edwards welcomed everyone in attendance and introduced the following speakers:
 - Soloman F. Odafe, MBBS, MPH, MSc, Immunization Services Division
 - Zoster Disease
 - Portia Knowlton, MHRM, Program Coordinator, HPV Cancer Prevention Program St. Jude
 - HPV Vaccination is Cancer Prevention

Zoster Disease:

- Soloman F. Odafe MBBS, MPH, MSc, Epidemic Intelligence Officer Immunization Services Division discussed the following:
 - Herpes Zoster (Shingles)
 - Reactivation of varicella zoster virus that causes chicken pox
 - Risk of infection increases with age and immunocompromised status
 - Risk of infection is lower among persons vaccinated against varicella
 - Painful blisters and burning sensation
 - Complications of Herpes Zoster (Shingles)
 - Postherpetic neuralgia (PHN)
 - Herpes zoster ophthalmicus
 - Dissemination with generalized skin eruptions and involvement of the central nervous system, lungs, liver, and pancreas
 - Epidemiology of Herpes Zoster in the United States
 - Approximately 1 million episodes occurred annually in the US in the pre-vaccine era
 - Lifetime risk of zoster estimated to be 32%
 - 50% of persons living until age 85 will develop zoster
 - Vaccine for Prevention of Zoster
 - Shingrix (RZV) is the only vaccine available
 - Zostavax is no longer available as of November 2020
 - Shingrix provides a higher level of protection compared to Zostavax
 - Two doses needed taken two to six months apart
 - Immunocompromised individuals can be given doses one to two months apart
 - Preferred injection site- deltoid muscle, alternate site- anterolateral thigh
 - Not recommended during pregnancy, can be given to breastfeeding mothers
 - Vaccine efficacy
 - Preventing Shingles: 97% 50-69 years; 91% 70 years and older
 - Preventing PHN: 91 % 50- 69 years; 89% 70 years and older
 - Storage and Handling
 - Store between 2- 8 degrees C
 - Administer immediately after reconstitution and used within 6 hours
 - Do not freeze
 - Shingrix Vaccine Administration Errors
 - Wrong route
 - Wrong vaccine
 - Improper storage
 - Wrong preparation
 - Wrong schedule
 - Staff unaware of the need for a second dose

HPV Vaccination is Cancer Prevention:

- Portia Knowlton, MHRM, Program Coordinator, HPV Cancer Prevention Program St. Jude discussed the following:
 - Overview of the St. Jude HPV Cancer Prevention Program
 - Vision- world free of HPV cancers
 - Mission- increase on-time HPV vaccination for all children through education, promotion, best practice models, and strategic partner engagement
 - Opportunities for HPV Vaccination and Cancer Prevention
 - Must have conversation between provider, child, and parents
 - Strong provider recommendation to drive rates up
 - Bundle HPV with Tdap, MenACWY at age 11-12
 - Emphasize age 9
 - Better change to complete two dose series by age 13
 - Risk of exposure increases at age 13
 - Best immune response at age 9
 - HPV Vaccination Coverage in the Southeast
 - Rates are historically the lowest: 60% completion rate, Healthy People Target goal: 80%
 - HPV Vaccination Roundtable of the Southeast discussion:
 - Current conditions surrounding HPV vaccination and HPV cancer prevention
 - Replication HPV vaccination success stories across the Southeast (Operation WIPE OUT)
 - Overcoming challenges facing HPV vaccination
 - Opportunities to improve HPV vaccination coverage in each state and the overall region
 - Priority actions
 - Develop and implement a communication campaign and messages for the Southeastern region
 - Develop and disseminate a plan for HPV cancer elimination in the Southeast
 - Accelerate efforts to start HPV vaccination at age 9

Next Steps/Adjourn:

- The meeting was adjourned by Ms. Edwards at 11:30 am. The next meeting was scheduled for July 23, 2024.